1-(4-AMinophenyl)-5,6-dihydro-3-(4-Morpholinyl)-2(1h)-pyridinone

‌Apixaban Intermediate (CAS 1267610-26-3)‌
Google Keywords: Apixaban Intermediate, CAS 1267610-26-3, Anticoagulant API Synthesis, Direct Factor Xa Inhibitors, GMP Pharmaceutical Intermediates

🌟 ‌Product Overview‌

‌Apixaban Intermediate‌ (CAS 1267610-26-3) is a high-purity chemical intermediate essential for synthesizing ‌Apixaban‌, a leading direct oral anticoagulant (DOAC) targeting Factor Xa to prevent thromboembolic disorders. This intermediate ensures precision and scalability in producing Apixaban API, meeting rigorous pharmaceutical standards for global anticoagulant drug development.

• ‌Primary Function‌: Serves as a critical building block in multi-step Apixaban API synthesis, enabling controlled chemical transformations.

• ‌Applications‌: Anticoagulant drug manufacturing, cardiovascular therapies, and large-scale API production.

✅ ‌Key Advantages‌

🔹 ‌Ultra-High Purity‌ | ≥99.5% (HPLC/GC verified) | Complies with ICH Q11 guidelines for intermediates.
🔹 ‌Optimized Synthesis‌ | High-yield process (>80% efficiency) with minimized impurities, reducing production costs and waste.
🔹 ‌Regulatory Compliance‌ | Fully characterized (NMR, HRMS, FTIR) to support FDA/EMA filings and GMP audits.

🧪 ‌Applications‌

• ‌API Production‌: Enables efficient synthesis of Apixaban with consistent batch-to-batch quality.

• ‌Process Development‌: Accelerates R&D in refining synthetic pathways for improved scalability and sustainability.

• ‌Quality Control‌: Used in analytical method validation and stability testing during API batch release.

📜 ‌Quality Assurance‌

• ‌Testing Methods‌: HPLC, GC, NMR, HRMS, and FTIR for structural confirmation and impurity profiling.

• ‌Standards‌: Meets USP <1086>, EP 10.0, and ISO 9001:2015 certified manufacturing protocols.

📈 ‌Market Trends‌

The ‌global anticoagulants market‌ is projected to reach ‌$27.5 billion by 2030‌ (CAGR 8.2%), driven by rising cases of atrial fibrillation, venous thromboembolism, and demand for safer oral anticoagulants like Apixaban. This intermediate is pivotal for scaling generic and novel Factor Xa inhibitor production post-patent expiries.

Elevate your anticoagulant production with Apixaban Intermediate – precision-engineered for purity, efficiency, and regulatory readiness.